Drug Trial Radar · NCT07083193
A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jan 20, 2025
Primary completion
Apr 20, 2026
Study completion Apr 20, 2026
Sponsor
- Lead sponsor
- Accro Bioscience (Suzhou) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis. The total study duration is up to 17 weeks, including 4-week screening, 12-week treatment period, and 1-week safety follow-up. The study will enroll approximately 24 participants with moderate to severe active ulcerative colitis.
Conditions
- Ulcerative Colitis
Interventions
AC-101Drug
AC-101 tablets will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse EventsTime frame: Up to Week 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.